Skip to main navigation
Skip to content

Infinity Pharmaceuticals, Inc

Search
  • Toggle search form
  • Follow us on Twitter
  • Connect with us on LinkedIn

Investor Relations

  • Our Team
    • Mission Values
    • Leadership Team
    • Board of Directors
    • Clinical Advisory Board
    • Scientific Advisory Board
  • Our Development Program
    • Our Pipeline
    • Eganelisib
    • PI3K-Gamma
    • Selected Publications
    • Expanded Access
    • For Patients
  • For Patients
  • Investors/Media
    • Press Releases
    • Events & Presentations
    • Corporate Governance
      • Executive Leadership
      • Board of Directors
      • Committees
    • Financial Information
      • SEC Filings
      • Annual Reports
      • Quarterly Results
    • Stock Information
      • Stock Quote & Chart
      • Historical Price Lookup
      • Investment Calculator
    • Analyst Coverage
    • Online Investor Kit
    • Information Request
  • Join Us
    • Our Community
    • Life at Infinity
    • Careers
    • Benefits
  • Contact Us

Press Releases

Q3 2022 Infinity Pharmaceuticals, Inc. Earnings Conference Call
Nov 14, 2022 at 8:30 AM EST
Listen to webcast

Keyword Search

  • Summary ToggleInfinity Pharmaceuticals Presents Updated Data from Phase 2 MARIO-275 Trial in Urothelial Cancer (UC) and Phase 2 MARIO-3 Trial in Triple Negative Breast Cancer (TNBC)
    July 27, 2021 at 7:31 AM EDT
  • Summary ToggleInfinity Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Company Update
    July 27, 2021 at 7:30 AM EDT
  • Summary ToggleInfinity Pharmaceuticals Hosting Webinar on MARIO-3 and MARIO-275 Phase 2 Trials
    July 20, 2021 at 8:35 AM EDT
  • Summary ToggleInfinity to Present at The Keystone Symposia Precision Oncology Meeting
    June 14, 2021 at 8:35 AM EDT
  • Summary ToggleInfinity Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Company Update
    May 13, 2021 at 4:05 PM EDT
  • Summary ToggleInfinity Announces the Date of Its First Quarter 2021 Financial Results Conference Call and Webcast
    May 6, 2021 at 7:35 AM EDT
  • Summary ToggleInfinity to Present at New York Academy of Sciences’ Frontiers in Cancer Immunotherapy 2021
    May 5, 2021 at 8:35 AM EDT
  • Summary ToggleInfinity to Present at the 7th Annual Truist Securities Life Sciences Summit
    April 27, 2021 at 8:35 AM EDT
  • Summary ToggleInfinity Pharmaceuticals Reports Full Year 2020 Financial Results and Provides Update on Eganelisib Development
    March 16, 2021 at 4:05 PM EDT
  • Summary ToggleInfinity to Present at the Oppenheimer & Co. Annual Healthcare Conference
    March 10, 2021 at 8:35 AM EST

Pagination

  • First page First
  • Previous page Previous
  • …
  • Page 3
  • Current page 4
  • Page 5
  • Page 6
  • …
  • Next page Next
  • Last page Last

Shareholder Tools

  • RSS Feeds

    RSS Feeds

  • Email Alerts

    Email Alerts

  • Print

    Print

  • Email

    Email

Infinity Pharmaceuticals, Inc.

1100 Massachusetts Ave
Cambridge, MA 02138
617-453-1000

Terms and Conditions

  • Terms & Conditions
  • Privacy Policy
  • Forward Looking Statements
Connect With Us
  • Twitter
  • LinkedIn

Our Team

  • Our Team
    • Mission Values
    • Leadership Team
    • Board of Directors
    • Clinical Advisory Board
    • Scientific Advisory Board

Our Development Program

  • Our Development Program
    • Our Pipeline
    • Eganelisib
    • PI3K-Gamma
    • Selected Publications
    • Expanded Access
    • For Patients

Investor / Media

  • Investors/Media
    • Press Releases
    • Events & Presentations
    • Corporate Governance
    • Financial Information
    • Stock Information
    • Analyst Coverage
    • Online Investor Kit
    • Information Request

Join Us

  • Join Us
    • Our Community
    • Life at Infinity
    • Careers
    • Benefits
© 2023 Infinity Pharmaceuticals, Inc. All Rights Reserved.